Seattle-based biotech firm Dendreon (NASDAQ:[[ticker:DNDN]]) yesterday reported data from an ongoing Phase III clinical trial of its drug sipuleucel-T (Provenge), saying that the drug caused long-term immune responses in patients with recurrent prostate cancer and whose prostates have been surgically removed. The data follows Dendreon’s whirlwind last week when shares of the company’s stock soared after it revealed that Provenge could prolong life of patients with prostate cancer with few side effects. Dendron’s stock was up 6.5 percent to $19.15 per share at 12:33 pm Eastern.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
